Osimertinib suppresses EGFR signaling and, when combined with 6-Thio-dG, is well-tolerated in vivo. (A) The indicated tumors at sizes of around 100 mm³ (n = 3) were treated with osimertinib (Osim; 5 mg/kg/day, og) for 18 (PC-9) or 21 (HCC827) days. SE, short exposure. (B–F) Treatments were the same as described in Fig. 7. Tumor growth is presented as a fold change in tumor sizes in comparison with their initial sizes of PDXs. Source data are available for this figure: SourceData FS5.